These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 26916220)

  • 1. Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.
    Mizukami T; Togashi Y; Naruki S; Banno E; Terashima M; de Velasco MA; Sakai K; Yoneshige A; Hayashi H; Fujita Y; Tomida S; Nakajima TE; Fujino T; Boku N; Ito A; Nakagawa K; Nishio K
    Mol Carcinog; 2017 Jan; 56(1):106-117. PubMed ID: 26916220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired resistance to EGFR-targeted therapies in colorectal cancer.
    Van Emburgh BO; Sartore-Bianchi A; Di Nicolantonio F; Siena S; Bardelli A
    Mol Oncol; 2014 Sep; 8(6):1084-94. PubMed ID: 24913799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts.
    Hegab AE; Ozaki M; Kameyama N; Gao J; Kagawa S; Yasuda H; Soejima K; Yin Y; Guzy RD; Nakamura Y; Ornitz DM; Betsuyaku T
    J Pathol; 2019 Oct; 249(2):193-205. PubMed ID: 31090071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.
    Efferth T
    Curr Med Chem; 2012; 19(33):5735-44. PubMed ID: 23033949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
    Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
    Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer.
    Wang G; He Y; Sun Y; Wang W; Qian X; Yu X; Pan Y
    Clin Transl Oncol; 2020 Jun; 22(6):813-822. PubMed ID: 31587152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The genomic landscape of response to EGFR blockade in colorectal cancer.
    Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
    Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis.
    Sahores A; May M; Sequeira GR; Fuentes C; Jacobsen B; Lanari C; Lamb CA
    Curr Cancer Drug Targets; 2018; 18(10):979-987. PubMed ID: 29237381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.
    Napolitano S; Matrone N; Muddassir AL; Martini G; Sorokin A; De Falco V; Giunta EF; Ciardiello D; Martinelli E; Belli V; Furia M; Kopetz S; Morgillo F; Ciardiello F; Troiani T
    J Exp Clin Cancer Res; 2019 Dec; 38(1):492. PubMed ID: 31842958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.
    Bardelli A; Corso S; Bertotti A; Hobor S; Valtorta E; Siravegna G; Sartore-Bianchi A; Scala E; Cassingena A; Zecchin D; Apicella M; Migliardi G; Galimi F; Lauricella C; Zanon C; Perera T; Veronese S; Corti G; Amatu A; Gambacorta M; Diaz LA; Sausen M; Velculescu VE; Comoglio P; Trusolino L; Di Nicolantonio F; Giordano S; Siena S
    Cancer Discov; 2013 Jun; 3(6):658-73. PubMed ID: 23729478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
    Takegawa N; Yonesaka K; Sakai K; Ueda H; Watanabe S; Nonagase Y; Okuno T; Takeda M; Maenishi O; Tsurutani J; Satoh T; Okamoto I; Nishio K; Tamura T; Nakagawa K
    Oncotarget; 2016 Jan; 7(3):3453-60. PubMed ID: 26657506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of
    Owen DR; Wong HL; Bonakdar M; Jones M; Hughes CS; Morin GB; Jones SJM; Renouf DJ; Lim H; Laskin J; Marra M; Yip S; Schaeffer DF
    Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29438965
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis.
    Pagano E; Borrelli F; Orlando P; Romano B; Monti M; Morbidelli L; Aviello G; Imperatore R; Capasso R; Piscitelli F; Buono L; Di Marzo V; Izzo AA
    Pharmacol Res; 2017 May; 119():227-236. PubMed ID: 28193521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF9-induced changes in cellular redox status and HO-1 upregulation are FGFR-dependent and proceed through both ERK and AKT to induce CREB and Nrf2 activation.
    Chuang JI; Huang JY; Tsai SJ; Sun HS; Yang SH; Chuang PC; Huang BM; Ching CH
    Free Radic Biol Med; 2015 Dec; 89():274-86. PubMed ID: 26424114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor-targeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models.
    Miyamoto Y; Muguruma N; Fujimoto S; Okada Y; Kida Y; Nakamura F; Tanaka K; Nakagawa T; Kitamura S; Okamoto K; Miyamoto H; Sato Y; Takayama T
    Cancer Sci; 2019 Jun; 110(6):1921-1930. PubMed ID: 30973663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DJ-1 promotes epithelial-to-mesenchymal transition via enhancing FGF9 expression in colorectal cancer.
    Li L; Zhang C; Li Y; Zhang Y; Lei Y
    Biol Open; 2020 May; 9(5):. PubMed ID: 32366371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
    Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A
    Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.